Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9161 in Primary Immune Thrombocytopenia
NCT04428255Phase 3Completed
- Sponsor
- Harbour BioMed
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of batoclimab in primary immune thrombocytopenia (ITP), sponsored by Harbour BioMed. Started Jul 2020; status: completed.
02
Drugs
batoclimab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04428255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428255.